HealthLynked Corp. Files 8-K on Director and Officer Changes
Ticker: HLYK · Form: 8-K · Filed: Jan 15, 2025 · CIK: 1680139
| Field | Detail |
|---|---|
| Company | Healthlynked Corp (HLYK) |
| Form Type | 8-K |
| Filed Date | Jan 15, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $66,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, executive-compensation, board-changes
TL;DR
HealthLynked Corp. filed an 8-K on Jan 15, 2025, reporting changes to its board and exec pay.
AI Summary
On January 15, 2025, HealthLynked Corp. filed an 8-K report detailing changes in its board of directors and executive compensation. The filing indicates a shift in corporate governance and potentially new compensation structures for its officers.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy, financial priorities, or operational direction.
Risk Assessment
Risk Level: medium — Changes in board and executive compensation can indicate internal shifts that may impact future performance or strategy.
Key Players & Entities
- HealthLynked Corp. (company) — Registrant
- January 15, 2025 (date) — Date of earliest event reported
- Nevada (jurisdiction) — State of incorporation
- Naples, FL (location) — Principal executive offices
FAQ
What specific changes were made to the board of directors?
The filing indicates changes related to the 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers', but the specific names and details of the changes are not provided in this summary section of the 8-K.
What are the details of the new compensatory arrangements?
The filing mentions 'Compensatory Arrangements of Certain Officers' as an item of disclosure, but the specific details of these arrangements are not elaborated upon in the provided text.
What is the primary purpose of this 8-K filing?
This 8-K filing serves as a current report to disclose significant events, specifically concerning changes in directors, officers, and executive compensation, as well as Regulation FD disclosures and financial statements/exhibits.
When was this report filed?
The report was filed on January 15, 2025.
Where is HealthLynked Corp. headquartered?
HealthLynked Corp. is headquartered at 1265 Creekside Parkway, Suite 302, Naples, FL 34108.
Filing Stats: 777 words · 3 min read · ~3 pages · Grade level 10.7 · Accepted 2025-01-15 16:06:48
Key Financial Figures
- $66,000 — ys per week and his base salary will be $66,000 per year. There are no arrangements or
Filing Documents
- ea0227787-8k_health.htm (8-K) — 29KB
- ea022778701ex99-1_health.htm (EX-99.1) — 11KB
- 0001213900-25-003828.txt ( ) — 210KB
- hlyk-20250115.xsd (EX-101.SCH) — 3KB
- hlyk-20250115_lab.xml (EX-101.LAB) — 33KB
- hlyk-20250115_pre.xml (EX-101.PRE) — 22KB
- ea0227787-8k_health_htm.xml (XML) — 3KB
02 Departure of Directors or Certain
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of Chief Financial Officer Effective January 15, 2025, HealthLynked Corp., a Nevada corporation (the " Company "), appointed Jeremy Daniel, age 48, as its part-time Chief Financial Officer, effective immediately. Mr. Daniel has also served as Chief Financial Officer for Innoveren Scientific, a publicly traded biotech firm, since 2019. Before his time at Innoveren, Mr. Daniel held the positions of Chief Financial Officer at Regenerative Medicine Solutions (2013-19) and at Sleep Apnea Treatment Centers of America, and Controller for Omnicare (2012-14). Mr. Daniel holds a Master of Business Administration in Business Administration from Xavier University and a Bachelor of Business Administration and Accounting from The University of Cincinnati. Mr. Daniel is also a Certified Public Accountant. The Company and Mr. Daniel have agreed that Mr. Daniel will work two days per week and his base salary will be $66,000 per year. There are no arrangements or understandings between Mr. Daniel and any other person pursuant to which he was selected for his position. In addition, there are no family relationships between Mr. Daniel and any directors or executive officers of the Company, and no transactions are required to be reported under Item 404(a) of Regulation S-K between Mr. Daniel and the Company. Departure of Chief Financial Officer Effective January 15, 2025, David Rosal tendered his resignation as Chief Financial Officer of the Company. Mr. Rosal's resignation is not a result of any disagreement between himself and the Company, its management, the Company's Board of Directors (the " Board ") or any committee of the Board. The Company appreciates Mr. Rosal's diligent service as Chief Financial Officer.
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. Furnished as Exhibit 99.1 of this Current Report on Form 8-K is a press release issued by the Company with regard to Mr. Daniel's appointment as Chief Financial Officer. The press release shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information in this Item 7.01 and Exhibit 99.1 of this Current Report on Form 8-K shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date of this Current Report, regardless of any general incorporation language in any such filing. 1
01. Financial Statements
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Exhibit Title or Description 99.1 Press Release dated January 15, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized. HEALTHLYNKED CORP. Date: January 15, 2025 /s/ Michael Dent Michael Dent Chief Executive Officer and Chairman 3